Medlab Clinical Ltd
ASX:MDC

Watchlist Manager
Medlab Clinical Ltd Logo
Medlab Clinical Ltd
ASX:MDC
Watchlist
Price: 6.6 AUD -4.21%
Market Cap: 15.1m AUD

MDC's latest stock split occurred on Aug 2, 2022

The company executed a 1-for-150 stock split, meaning that for every 150 shares held, investors received 1 new share.

Before the split, MDC traded at 0.088 per share. Afterward, the share price was about 10.1.

The adjusted shares began trading on Aug 2, 2022. This was MDC's 2nd stock split, following the previous one in Jul 20, 2016.

Last Splits:
Aug 2, 2022
1-for-150
Jul 20, 2016
35-for-34
Pre-Split Price
13.2 0.088
Post-Split Price
10.1
Before
After
Last Splits:
Aug 2, 2022
1-for-150
Jul 20, 2016
35-for-34

Medlab Clinical Ltd
Stock Splits History

MDC Stock Splits Timeline
Aug 2, 2022
Aug 2, 2022
Split 1-for-150
/0.0066666666666667
Pre-Split Price
13.2 0.088
Post-Split Price
10.1
Before
After
Jul 20, 2016
Jul 20, 2016
Split 35-for-34
x1.0294117647059
Pre-Split Price
61.2 0.42
Post-Split Price
60.75
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.1377 0.1377 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.57 8.57 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 7, 2026
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
1-for-10
/10
0.35 0.35 EUR N/A
Load More

Medlab Clinical Ltd
Glance View

Market Cap
15.1m AUD
Industry
Biotechnology

Medlab Clinical Ltd. engages in the development of therapeutic pathways for diagnosed chronic diseases. The company is headquartered in Alexandria, New South Wales. The company went IPO on 2015-07-14. Medlab’s pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. The firm's lead drug candidate, NanaBis, is under development for cancer bone pain as an alternative to opioid use. The firm also has a drug delivery platform called NanoCelle, which is wholly owned by Medlab and developed in Medlab’s owned Office of the Gene Technology Regulator (OGTR) registered laboratory. NanoCelle is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia, United States, and the United Kingdom.

MDC Intrinsic Value
0.12 AUD
Overvaluation 98%
Intrinsic Value
Price
Back to Top